Medtronic says a study of its InterStim neurostimulation device shows it's better than medication alone for treating less-severe overactive bladder syndrome.
Medtronic (NYSE:MDT) is touting positive results from a study of its InterStim sacral nerve stimulator for treating less-severe overactive bladder syndrome, saying the device produces "superior efficacy and quality of life" compared with medication alone.
Covidien’s 3-year study results showing positive outcomes for its Urgent PC Neuromodulation system in...
NEC Display Solutions wins 510(k) clearance for its 21-inch medical monitor systems.
J&J's former head of global cardiology makes the jump to CEO at Itamar Medical
Sunshine Heart raises $1.5 million of a hoped-for $25.5 million equity funding round.
J&J subsidiary Lifescan asks the courts to ban Shasta from using its logo, saying problems with...